Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens.
10.3346/jkms.2016.31.4.510
- Author:
Shin Young HYUN
1
;
Sang Hoon HAN
;
Soo Jeong KIM
;
Ji Eun JANG
;
Yundeok KIM
;
Hyunsoo CHO
;
Jung Yeon LEE
;
June Won CHEONG
;
Yoo Hong MIN
;
Jae Woo SONG
;
Jin Seok KIM
Author Information
1. Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. hemakim@yuhs.ac
- Publication Type:Original Article
- Keywords:
Multiple Myeloma;
Infection;
Bortezomib;
Lymphopenia;
Performance Status
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use;
Bacterial Infections/*complications/microbiology;
Bortezomib/*administration & dosage;
Female;
Gram-Negative Bacteria/isolation & purification;
Gram-Positive Bacteria/isolation & purification;
Humans;
Lymphocyte Count;
Lymphopenia/*therapy;
Male;
Middle Aged;
Multiple Myeloma/complications/*drug therapy/mortality;
Multivariate Analysis;
Proportional Hazards Models;
Retrospective Studies;
Risk Factors;
Stem Cell Transplantation;
Survival Rate;
Transplantation, Homologous
- From:Journal of Korean Medical Science
2016;31(4):510-518
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 10(9)/L, P = 0.043) were confirmed as independent risk factors. The probability of developing SBI were 5.1%, 14.9%, 23.9% and 59.5% in courses with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors associated with SBI in each course of bortezomib treatment. Therefore, MM patients with these risk factors should be more closely monitored for the development of SBI during bortezomib-based treatment.
